Next generation designer virus-like particle vaccines for dengue

References

• Bhatt S, Gething PW, Brady OJ, et al. The global distribution and burden of dengue. Nature. 2013;496:504–507.
   PubMed Web of Science ®Google Scholar
• Pierson TC, Diamond MS. Fields virology. In: Knipe DM, Howley PM, editors. Flaviviruses. 6th ed. Philadelphia: Wolters Kluwer and Lippincott Williams & Wilkins; 2013. p. 747–794.
   Google Scholar
• Halstead SB. Neutralization and antibody dependent enhancement of dengue viruses. Adv Virus Res. 2003;60:421–467.
   PubMed Web of Science ®Google Scholar
• Murphy BR, Whitehead SS. Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol. 2011;29:587–619.
   PubMed Web of Science ®Google Scholar
• Swaminathan S, Batra G, Khanna N. Dengue vaccines: state of the art. Expert Opin Ther Pat. 2010;20:819–835.
   PubMed Web of Science ®Google Scholar
• Vannice KS, Wilder-Smith A, Barrett ADT, et al. WHO report: clinical development and regulatory points for consideration for second-generaton live attenuated dengue vaccines. Vaccine. 2018;36:3411–3417.
   PubMed Web of Science ®Google Scholar
• Dengue and dengue hemorrhagic fever. World Health Organization Factsheet N°117; 2017 [cited 2018 Dec 14]. Available from: http://www.who.int/en/news-room/fact-sheets/detail/dengue-and-severe-dengue
   Google Scholar
• Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. New Engl J Med. 2015;373:1195–1206.
   PubMed Web of Science ®Google Scholar
• Guy B, Jackson N. Dengue vaccine: hypothesis to understand CYD-TDV-induced protection. Nature Rev Microbiol. 2016;14:45–54.
   PubMed Web of Science ®Google Scholar
• Whitehead SS. Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYDTM vaccine? Exp Rev Vac. 2016;15:509–517.
   PubMed Web of Science ®Google Scholar
• Osorio JE, Wallace D, Stinchcomb DT. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone. Exp Rev Vac. 2016;15:497–508.
   PubMed Web of Science ®Google Scholar
• Lam JH, Ong LC, Alonso S. Key concepts, strategies, and challenges in dengue vaccine development: an opportunity for sub-unit candidates? Exp Rev Vac. 2016;15:483–495.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Li S, Yu H, et al. Virus-like particle-based human vaccines: quality assessment based on structural and functional properties. Trends Biotechnol. 2013;31:654–663.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, et al. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017;34:123–132.
   PubMed Web of Science ®Google Scholar
• Wu T, Li SW, Zhang J, et al. Hepatitis E vaccine development: a 14 year odyssey. Hum Vaccin Immunother. 2012;8:823–827.
   PubMed Web of Science ®Google Scholar
• Vannice KS, Durbin A, Hombach J. Status of vaccine research and development of vaccines for dengue. Vaccine. 2016;34:2934–2938.
   PubMed Web of Science ®Google Scholar
• Ramasamy V, Arora U, Shukla R, et al. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice. PLoS Negl Trop Dis. 2018;12:e0006191.
   PubMed Web of Science ®Google Scholar
• Rajpoot RK, Shukla R, Arora U, et al. Dengue envelope-based ‘four-in-one’ virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralizing antibodies in mice. Sci Rep. 2018;8:8643.
   PubMed Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, et al. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA. 2003;100:6986–6991.
   PubMed Web of Science ®Google Scholar
• Beltramello M, Williams KL, Simmons CP, et al. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe. 2010;8:271–283.
   PubMed Web of Science ®Google Scholar
• De Alwis R, Beltramello M, Messer WB, et al. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl Trop Dis. 2011;5:e1188.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16:170–177.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Jumnainsong A, Onsirisakul N, et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science. 2010;328:745–748.
   PubMed Web of Science ®Google Scholar
• Da Silva Voorham JM, Rodenhuis-Zybert IA, Nunez NVA, et al. Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One. 2012;7:e29957.
   PubMed Web of Science ®Google Scholar
• De Alwis R, Williams KL, Schmid MA, et al. Dengue viruses are enhanced by distinct populations of serotype cross-reactive antibodies in human immune sera. PLoS Pathog. 2014;10:e1004386.
   PubMed Web of Science ®Google Scholar
• De Alwis R, Smith SA, Olivarez NP, et al. Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci USA. 2012;109:7439–7444.
   PubMed Web of Science ®Google Scholar
• Teoh EP, Kukkaro P, Teo EW, et al. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci Transl Med. 2012;4:139ra83.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, et al. A potent anti-dengue human antibody preferentially recognizes the conformation of E protein monomers assembled on the virus surface. EMBO Mol Med. 2014;6:358–371.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Ibarra KD, Ng TS, et al. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers. Science. 2015;349:88–91.
   PubMed Web of Science ®Google Scholar
• Sukupolvi-Petty S, Austin SK, Purtha WE, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol. 2007;81:12816–12826.
   PubMed Web of Science ®Google Scholar
• Gromowski GD, Barrett ADT. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology. 2007;366:349–360.
   PubMed Web of Science ®Google Scholar
• Guzman MG, Hermida L, Bernardo L, et al. Guillen. Domain III of the envelope protein as a dengue vaccine target. Exp Rev Vac. 2010;9:137–147.
   PubMed Web of Science ®Google Scholar
• Rey FA, Stiasny K, Vaney MC, et al. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 2018;19:e45302.
   Web of Science ®Google Scholar
• Kuhn RJ, Zhang W, Rossman MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell. 2002;108:717–725.
   PubMed Web of Science ®Google Scholar
• Mani S, Tripathi L, Raut R, et al. Pichia pastoris-expressed dengue 2 envelope forms virus-like particles without pre-membrane protein and induces high titer neutralizing antibodies. PLoS One. 2013;8:e64595.
   PubMed Web of Science ®Google Scholar
• Tripathi L, Mani S, Raut R, et al. Pichia pastoris-expressed dengue 3 envelope-based virus-like particles elicit predominantly domain III-focused high titer neutralizing antibodies. Front Microbiol. 2015;6:1005.
   PubMed Web of Science ®Google Scholar
• Poddar A, Ramasamy V, Shukla R, et al. Virus-like particles derived from Pichia pastoris-expressed dengue virus type 1 glycoprotein elicit homotypic virus-neutralizing envelope domain III-directed antibodies. BMC Biotechnol. 2016;16:50.
   PubMed Web of Science ®Google Scholar
• Khetarpal N, Shukla R, Rajpoot RK, et al. Recombinant dengue virus 4 envelope glycoprotein virus-like particles derived from Pichia pastoris are capable of eliciting homotypic domain III-directed neutralizing antibodies. Am J Trop Med Hyg. 2017;96:126–134.
   PubMed Web of Science ®Google Scholar
• Chin JFL, Chu JJH, Ng ML. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microb Infect. 2007;9:1–6.
   PubMed Web of Science ®Google Scholar
• Chen Y, Maguire T, Hileman RE, et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nature Med. 1997;3:866–871.
   PubMed Web of Science ®Google Scholar
• Huerta V, Chinea G, Fleitas N, et al. Characterization of the interaction of domain III of the envelope protein of dengue virus with putative receptors from CHO cells. Virus Res. 2008;137:225–234.
   PubMed Web of Science ®Google Scholar
• Crill WD, Roehrig RT. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to vero cells. J Virol. 2001;75:7769–7773.
   PubMed Web of Science ®Google Scholar
• Watanabe S, Chan KWK, Wangm J, et al. Dengue virus infection with highly neutralizing levels of cross-reactive antibodies causes acute lethal small intestinal pathology without a high level of viremia in mice. J Virol. 2015;89:5847–5861.
   PubMed Web of Science ®Google Scholar
• Robinson LN, Tharakaraman K, Rowley KJ, et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell. 2015;162:493–504.
   PubMed Web of Science ®Google Scholar
• Shukla R, Rajpoot RK, Arora U, et al. Pichia pastoris-expressed bivalent virus-like particulate vaccine induces domain III-focused bivalent neutralizing antibodies without antibody-dependent enhancement in vivo. Front Microbiol. 2018;8:2644.
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Volpe KE, Squires J, et al. Contribution of disulfide bridging to epitope expression of the dengue type 2 virus envelope glycoprotein. J Virol. 2004;78:2648–2652.
   PubMed Web of Science ®Google Scholar
• Etemad B, Batra G, Raut R, et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg. 2008;79:353–363.
   PubMed Web of Science ®Google Scholar
• Wahala WMPB, Kraus AA, Haymore LB, et al. Dengue virus neutralization by human immune sera: role of envelope protein domain III-reactive antibody. Virology. 2009;392:103–113.
   PubMed Web of Science ®Google Scholar
• Frietze KM, Peabody DS, Chackerian B. Engineering virus-like particles as vaccine platforms. Curr Opin Virol. 2016;18:44–49.
   PubMed Web of Science ®Google Scholar
• Frey S, Castro A, Arsiwala A, et al. Bionanotechnology for vaccine design. Curr Opin Biotechnol. 2018;52:80–88.
   PubMed Web of Science ®Google Scholar
• Manolova V, Flace A, Bauer M, et al. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol. 2008;38:1404–1413.
   PubMed Web of Science ®Google Scholar
• Zabel F, Kündig TM, Bachmann MF. Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol. 2013;3:357–362.
   PubMed Web of Science ®Google Scholar
• Kushnir N, Streatfield SJ, Yusibov V. Virus-like particles as a highly efficient vaccine platform: diversity of targets and production systems and advances in clinical development. Vaccine. 2012;31:58–83.
   PubMed Web of Science ®Google Scholar
• Donaldson B, Lateef Z, Walker GF, et al. Virus-like particle vaccines: immunology and formulation for clinical translation. Exp Rev Vac. 2018;17:833–849.
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol. 1993;67:6929–6936.
   PubMed Web of Science ®Google Scholar
• Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Exp Rev Vac. 2011;10:589–599.
   PubMed Web of Science ®Google Scholar
• Fuenmayor J, Godia F, Cervera L. Production of virus-like particles. New Biotechnol. 2017;39:174–180.
   PubMed Web of Science ®Google Scholar
• Bill RM. Recombinant protein subunit vaccine synthesis in microbes: a role for yeast? J Pharm Pharmacol. 2014;67:319–328.
   PubMed Web of Science ®Google Scholar
• Ciofalo V, Barton N, Kreps J, et al. Safety evaluation of a lipase enzyme preparation, expressed in Pichia pastoris, intended for use in the degumming of edible vegetable oil. Regul Toxicol Pharmacol. 2006;45:1–8.
   PubMed Web of Science ®Google Scholar
• Cregg JM, Tolstorukov I, Kusari A, et al. Expression in the yeast Pichia pastoris. Meth Enzymol. 2009;463:169–189.
   PubMed Web of Science ®Google Scholar
• Byrne B. Pichia pastoris as an expression host for membrane protein structural biology. Curr Opin Struct Biol. 2015;32:9–17.
   PubMed Web of Science ®Google Scholar
• Shekar C. Pichia power: India’s biotech industry puts unconventional yeast to work. Chem Biol. 2008;15:201–202.
   PubMedGoogle Scholar
• Thompson CA. FDA approves kallikrein inhibitor to treat hereditary angioedema. Am J Health-Syst Pharm. 2010;67:93.
   PubMed Web of Science ®Google Scholar
• Ahmad M, Hirz M, Pichler H, et al. Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production. Appl Microbiol Biotechnol. 2014;98:5301–5317.
   PubMed Web of Science ®Google Scholar
• Cereghino GPL, Cereghino JL, Ilgen C, et al. Production of recombinant proteins in fermenter cultures of the yeast. Pichia pastoris Curr Opin Biotechnol. 2002;13:329–332.
   PubMed Web of Science ®Google Scholar
• Cereghino JL, Cregg JM. Heterologous protein expression in the methylotrophic yeast Pichia pastoris. FEMS Microbiol. 2000;24:45–66.
   PubMed Web of Science ®Google Scholar
• Gurramkonda C, Adnan A, Gabel T, et al. Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: application to intracellular production of hepatitis B surface antigen. Microb Cell Fact. 2009;8:13.
   PubMed Web of Science ®Google Scholar
• Gurramkonda C, Polez S, Skoko N, et al. Application of simple fed-batch technique to high-level secretory production of insulin precursor using Pichia pastoris with subsequent purification and conversion to human insulin. Microb Cell Fact. 2010;9:31.
   PubMed Web of Science ®Google Scholar
• De Schutter K, Lin YC, Tiels P, et al. Genome sequence of the recombinant protein production host Pichia pastoris. Nature Biotechnol. 2009;27:561–566.
   PubMed Web of Science ®Google Scholar
• Gasser B, Prielhofer R, Marx H, et al. Pichia pastoris: protein production host and model organism for biomedical research. Future Microbiol. 2013;8:191–208.
   PubMed Web of Science ®Google Scholar
• Kurtzman CP. Biotechnological strains of Komagatella (Pichia) pastoris are Komagatella phaffi as determined from multigene sequence analysis. J Ind Microbiol Biotechnol. 2009;36:1435–1438.
   PubMed Web of Science ®Google Scholar
• Chakma J, Masum H, Perampaladas K, et al. Indian vaccine innovation: the case of Shantha biotechnics. Globalization Health. 2011;7:9.
   PubMed Web of Science ®Google Scholar
• FDA approval of Jetrea: CDER list of licensed biological products with (1) Reference product exclusivity and (2) Biosimilarity or interchangeability evaluations to date; 2012 [cited 2018 Dec 14]. Available from: https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM411909.pdf
   Google Scholar
• Wang M, Jiang S, Wang Y. Recent advances in the production of recombinant subunit vaccines in Pichia pastoris. Bioengineered. 2016;7:155–165.
   PubMed Web of Science ®Google Scholar
• Sirima SB, Durier C, Kara L, et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or alhydrogel in European and African adults: a phase 1a/1b, randomized, double-blind multi-centre trial. Vaccine. 2017;35:6218–6227.
   PubMed Web of Science ®Google Scholar
• Thera MA, Coulibay D, Kone AK, et al. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara. Malaria J. 2016;15:442.
   PubMed Web of Science ®Google Scholar
• Remarque EJ, Roestenberg M, Younis S, et al. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults. PLoS One. 2012;7:e38898.
   PubMed Web of Science ®Google Scholar
• Khetarpal N, Poddar A, Nemani SK, et al. Dengue-specific subviral nanoparticles: design, creation and characterization. J Nanobiotechnol. 2013;11:5.
   PubMed Web of Science ®Google Scholar
• Arora U, Tyagi P, Swaminathan S, et al. Chimeric Hepatitis B core antigen virus-like particles displaying the envelope domain III of dengue virus type 2. J Nanobiotechnol. 2012;10:30.
   PubMed Web of Science ®Google Scholar
• Arora U, Tyagi P, Swaminathan S, et al. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice. Vaccine. 2013;31:873–878.
   PubMed Web of Science ®Google Scholar
• Pierson TC, Xu Q, Nelson S, et al. The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe. 2007;1:135–145.
   PubMed Web of Science ®Google Scholar
• Liu W, Jiang H, Zhou J, et al. Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties. Virus Genes. 2010;40:53–59.
   PubMed Web of Science ®Google Scholar
• Kuwahara M, Konishi E. Evaluation of extracellular subviral particles of dengue virus type 2 and Japanese encephalitis virus produced by Spodoptera frugiperda cells for use as vaccine and diagnostic antigens. Clin Vac Immunol. 2010;17:1560–1566.
   PubMed Web of Science ®Google Scholar
• Wang PG, Kudelko M, Lo J, et al. Efficient assembly and secretion of recombinant subviral particles of the four dengue serotypes using native prM and E proteins. PLoS One. 2009;4:e8325.
   PubMed Web of Science ®Google Scholar
• Henein S, Swanstrom J, Byers AM, et al. Dissecting antibodies induced by a chimeric yellow fever-dengue, live attenuated, tetravalent dengue vaccine (CYD-TDV) in naïve and dengue-exposed individuals. J Infect Dis. 2017;125:351–358.
   Google Scholar
• Halstead SB, Russell PK. Protective and immunological behavior of chimeric yellow fever dengue vaccine. Vaccine. 2016;34:1643–1647.
   PubMed Web of Science ®Google Scholar
• Halstead SB, Mahalingam S, Marovich MA, et al. Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010;10:712–722.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vac Immunol. 2010;17:1055–1065.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Harris E. Participants in the summit on dengue immune correlates of protection. Conference report, immune correlates of protection for dengue: state of the art and research agenda. Vaccine. 2017;35:4659–4669.
   PubMed Web of Science ®Google Scholar
• Duangchinda T, Dejnirattisai W, Vasanawathana S, et al. Immunodominant T-cell responses to dengue virus NS3 are associated with DHF. Proc Natl Acad Sci USA. 2010;107:16922–16927.
   PubMed Web of Science ®Google Scholar
• Katzelnick LC, Montoya M, Gresh L, et al. Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort. Proc Natl Acad Sci USA. 2016;113:728–733.
   PubMed Web of Science ®Google Scholar
• Buddhari D, Aldstadt J, Endy TP, et al. Dengue virus neutralizing antibody levels associated with protection from infection in Thai cluster studies. PLoS Negl Trop Dis. 2014;8:e3230.
   PubMed Web of Science ®Google Scholar
• Chau NB, Hieu NT, Anders KL, et al. Dengue virus infections and maternal antibody decay in a prospective birth cohort study of Vietnamese infants. J Infect Dis. 2009;200:1893–1900.
   PubMed Web of Science ®Google Scholar
• Libraty DH, Acosta LP, Tallo V, et al. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 2009;6:e1000171.
   PubMed Web of Science ®Google Scholar
• Kuhn J, Dowd KA, Post CB, et al. Shake, rattle, and roll: impact of the dynamics of flavivirus particles on their interactions with the host. Virology. 2015;479–480:508–517.
   PubMed Web of Science ®Google Scholar
• Saez-Llorens X, Tricou V, Yu D, et al. Immunogenicity and safety of one versus two doses of tetravalent dengue vaccine in healthy children aged 2–17 years in Asia and Latin America: 18-month interim data from a phase 2, randomized, placebo-controlled study. Lancet Infect Dis. 2018;18:162–170.
   PubMed Web of Science ®Google Scholar
• Whitehead SS, Durbin AP, Pierce KK, et al. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Negl Trop Dis. 2017;11:e0005584.
   PubMed Web of Science ®Google Scholar